Latest Breaking News On - Global clinical development at abraxis bioscience - Page 1 : comparemela.com

Share this article Share this article BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma s Board since November 2020, and resigns that post in conjunction with his appointment. The Company is also pleased to announce that Jeffrey S. Miller, M.D., who has supported GT Biopharma as the Company s Consulting Chief Medical Officer since August 2019, will become the Company s Consulting Chief Scientific Officer. Dr. Miller, with his colleagues at the University of Minnesota, is the inventor of the novel TriKE™ technology platform. Dr. Miller will continue his leadership role with respect to the design a

Julie seidelJeff millerGregory berkSusan roushJeffreys millerAnthonyj cataldoDavid castanedaBeverly hillsPrnewswire gt biopharma incBoard member of sideris pharmaceuticalsGlobal clinical development at abraxis bioscienceStern investor relations incSource gt biopharma incCompany consultingExchange commissionWeill medical college of cornell university